Krebs Biochemicals & Industries Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve The Company has enclosed herewith intimation for Board Meeting to be held on 29.10.2026 inter-alia, to consider and adopt the unaudited financial results for the 2nd quarter and half year ended September 30, 2026

Krebs Biochemicals & Industries Limited CIN: L24110AP1991PLC103912 October 16, 2026 To, To, BSE Limited National Stock Exchange of India Ltd P J Towers, Dalal Street, Exchange Plaza, Bandra Kurla Complex, Fort, Mumbai- 400001. Bandra(E), Mumbai- 400051. Scrip Code : 524518 Scrip Code : KREBSBIO Sub: Intimation of Board Meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir/ Madam, Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Notice is hereby given that meeting of the Board of Directors of the Company will be held on Thursday, October 29, 2026, inter-alia, to consider and adopt the unaudited financial results for the 2nd quarter and half year ended September 30, 2026. Further, with reference to the above meeting of the Board of Directors, we have already informed vide our letter dated September 21, 2026 that the trading window for dealing in the securities of the Company by the Insiders as defined under the SEBI (Prohibition of Insider Trading) Regulations, 2015 shall remain closed with effect from closure of business hours on September 30, 2026 and until 48 hours after the declaration of the Company’s unaudited financial results for the 2nd quarter and half year ended September 30, 2026. Thanking you, Yours Faithfully, For Krebs Biochemicals and Industries Limited Rakesh R Kalbate Company Secretary & Compliance Officer ACS 66666 Regd. Office : Kothapalli (V), Kasimkota (M), Anakapalli, Visakhapatnam, Andhra Pradesh-531 031 Tel : 040-66808040, Website: www.krebsbiochem.com, Email: com_sec@krebsbiochem.com